Go to interview with Enza Esposito Luke, RN, MSN, ONP
Go to interview with Robert W Carlson, MD
Go to interview with with Steven Shak, MD
Interview with a Woman with Breast Cancer and Her Mother
Go to interview with with Eric P Winer, MD
Go to interview with with William J Gradishar, MD
 
 
To listen to individual tracks now, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
 
     
Enza Esposito Luke, RN, MSN, ONP
Oncology Nurse Practitioner
Hematology/Oncology Medical
Group of Orange County
Orange, California
  
  Click here to download the entire interview  
     
Track 1 Introduction
Track 2 Case presentation: A 53-year-old woman with ER/PR-positive, HER2-negative, node-negative
breast cancer
Track 3 Use of Oncotype DX™ assay to facilitate decision-making regarding adjuvant chemotherapy
Track 4 Impact of experience as an oncology nurse on approach to patient care
Track 5 Selection of adjuvant hormonal therapy for perimenopausal patients
     
Robert W Carlson, MD
Professor of Medicine
Division of Oncology and
Stanford Medical Informatics
Stanford University Medical Center
Stanford, California
  
  Click here to download the entire interview  
     
Track 1 Introduction
Track 2 Quality control of ER/PR testing
Track 3 Benefit of adjuvant hormonal therapy for postmenopausal patients with ER-positive disease
Track 4 Mechanisms of action of different hormonal therapies
Track 5 Side effects associated with tamoxifen
Track 6 Incidence of endometrial cancer in patients receiving tamoxifen
Track 7 Rationale for lack of effectiveness of aromatase inhibitors in premenopausal patients
Track 8 Duration of adjuvant hormonal therapy
Track 9 Efficacy and tolerability of anastrozole versus tamoxifen
Track 10 Side effects associated with aromatase inhibitors
Track 11 Risk of bone loss and fractures associated with aromatase inhibitors
Track 12 Selection of adjuvant hormonal therapy for postmenopausal women with ER-positive disease
Track 13 Selection of a specific aromatase inhibitor
Track 14 Adjuvant endocrine therapy for premenopausal patients with ER-positive disease
Track 15 Clinical use of ovarian ablation for premenopausal patients
Track 16 Utility of the Oncotype DX assay in estimating the benefit of adjuvant chemotherapy
     
Steven Shak, MD
Chief Medical Officer
Genomic Health Inc
Redwood City, California
  
  Click here to download the entire interview  
     
Track 1 Introduction
Track 2 Importance of diagnostic techniques in the future of cancer treatment
Track 3 Rationale for and development of the Oncotype DX assay
Track 4 Clinical validation of the Oncotype DX assay
Track 5 Potential cost effectiveness of using the Oncotype DX assay
Track 6 Future directions with the Oncotype DX assay
Track 7 Clinical benefits of the development of the Oncotype DX assay
     
  Interview with a Woman with Breast Cancer and Her Mother
  
  Click here to download the entire interview  
     
Track 1 Introduction
Track 2 Personal perspective on living with breast cancer
Track 3 A mother’s experience with her daughter’s breast cancer
     
Eric P Winer, MD
Director, Breast Oncology Center
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
  
  Click here to download the entire interview  
     
Track 1 Introduction
Track 2 Design and results of adjuvant trastuzumab trials
Track 3 Role of adjuvant trastuzumab in node-negative, HER2-positive breast cancer
Track 4 BCIRG 006: Adjuvant trastuzumab with a nonanthracycline-containing regimen
Track 5 Cardiac toxicity associated with trastuzumab
Track 6 Strategies to monitor cardiac function in patients on adjuvant trastuzumab
Track 7 Rationale to assess alternative adjuvant approaches with trastuzumab in patients with low-risk HER2-positive disease
Track 8 ECOG-E2100: Paclitaxel with or without bevacizumab as first-line therapy for metastatic disease
Track 9 Tolerability of bevacizumab
Track 10 Clinical use of bevacizumab with chemotherapeutic agents other than paclitaxel
Track 11 Potential role of fulvestrant after five years of an aromatase inhibitor
Track 12 Efficacy and tolerability of fulvestrant
     
William J Gradishar, MD
Director, Breast Medical Oncology
Associate Professor of Medicine
Robert H Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
  
  Click here to download the entire interview  
     
Track 1 Introduction
Track 2 Biologic rationale for benefits of nanoparticle albumin-bound (nab) paclitaxel versus paclitaxel
Track 3 Comparative efficacy of nab paclitaxel, paclitaxel and docetaxel
Track 4 Potential differences in neuropathy associated with nab paclitaxel and paclitaxel
Track 5 Benefits of avoiding steroid premedication
Track 6 Dose and schedule of nab paclitaxel
Track 7 Future directions with nab paclitaxel
Track 8 Rationale, background and design of the EFECT trial